Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Bausch & Lomb (NYSE:BLCO)

Bausch + Lomb ends development of its glaucoma drug candidate BL1107, shifting the program to a new use after a Phase 2 failure. The company said BL1107, tested as a topical treatment, did not meet the primary endpoint of improving visual field mean deviation after 28 days in a randomized, double-masked, three-arm Phase 2 trial. The study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension, and key secondary visual-function measures also were not achieved. At the same time, BL1107 reduced intraocular pressure at Day 28, satisfying one secondary endpoint, while safety remained consistent with prior experience. Instead, Bausch + Lomb will advance BL1107 as a sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028. The company will continue collaborating with Ripple Therapeutics and noted shares fell 1.42% to $16.49.